We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microfluidics-Based System Can Speed DNA Analysis

By LabMedica International staff writers
Posted on 10 Nov 2010
The multistep process needed for conventional DNA analysis requiring 8-10 hours can be completed in less than 60 minutes using a microfluidics-based system.

Data supported the capability of an integrated miniaturized system to produce rapid, automated, "sample in-answer out” analyses for accurate human identification, using standard buccal swab samples.

ZyGEM Corp. More...
Ltd., (Charlottesville, VA, USA) announced several developments supporting the advancement of its integrated microfluidics platform designed to dramatically decrease the time, complexity, and cost of conducting DNA testing.

The data were presented at the 21st International Symposium on Human Identification (ISHI), which was held October 11-14, 2010, in San Antonio (TX, USA). Scientists from ZyGEM's MicroLab unit together with the company's collaborators presented three sets of studies illustrating how the component elements of the prototype RapI.D. system act to speed the DNA analysis process.

RapI.D., which ZyGEM is developing in collaboration with Lockheed Martin), leverages MicroLab's advanced microfluidic research to accelerate the DNA identification process—essentially building a laboratory on a microfluidic chip that dramatically reduces the processing steps, time, and effort needed for analysis.

Three studies were presented at ISHI: the first study showed how the ZyGEM system conducts polymerase chain reaction (PCR) amplification up to 10 times more rapidly than conventional approaches, primarily by using infrared-mediated microchip PCR to reduce the time required for thermal cycling and holding. Infrared-mediated microchip PCR used far less reagent, required less sample, and was compatible with commercially available short tandem repeat (STR) amplification kits.

A second study presented at ISHI demonstrated that rapid microfluidic separations using the ZyGEM approach could be performed on two different detection systems using a plastic microchip, rather than the conventional glass microchip. The much cheaper plastic microchips worked as well as their glass counterparts, and could substantially decrease the overall cost of the analysis.

A third ISHI study assessed the overall performance of the prototype integrated microfluidics-based RapI.D. DNA analysis system ZyGEM is developing with Lockheed Martin. It showed that the multistep process for conventional forensic STR analysis requiring 8-10 hours was completed by the RapI.D. system in less than 60 minutes, extracting DNA from crude samples in as little as four minutes and completing the PCR amplification process in less than 40 minutes, using commercially available reagents.

Related Links:
ZyGEM Corp. Ltd.
Lockheed Martin


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Immunofluorescence Analyzer
IFA System
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.